Trevi Therapeutics (TRVI) Stock Forecast for 2023 – 2026. Sell or Buy?
Updated: December 6, 2023 (06:04)
Sector: HealthcareThe share price of Trevi Therapeutics, Inc. (TRVI) now
50/200 Day Moving Average: $1.799 / $2.204
This figure corresponds to the Average Price over the previous 50/200 days. For Trevi Therapeutics stocks, the 50-day moving average is the resistance level today.
For Trevi Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Trevi Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Trevi Therapeutics stock price in 2024, 2025, 2026, 2027, 2028. How much will one Trevi Therapeutics share be worth in 2024 - 2028?
When should I take profit in Trevi Therapeutics stock? When should I record a loss on Trevi Therapeutics stock? What are analysts' forecasts for Trevi Therapeutics stock? What is the future of Trevi Therapeutics stock? We forecast Trevi Therapeutics stock performance using neural networks based on historical data on Trevi Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Trevi Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Trevi Therapeutics shares. This happens once a day.
Historical and forecast chart of Trevi Therapeutics stock
The chart below shows the historical price of Trevi Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Trevi Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
Trevi Therapeutics Inc. is a clinical biopharmaceutical company focused on the development and commercialization of Nalbuphine ER for the treatment of neurologically mediated conditions. The company is developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LD), in patients with Parkinson’s disease. The company is conducting phase 2b/3 clinical trials for nalbuphine ER. The company has also initiated a phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics, and antipruritic effect of nalbuphine ER in this population. The Company’s nalbuphine development programs for ER include the Chronic Pruritus Program, the Nodular Pruritus Program, the Chronic Liver Disease Pruritus Program, and the Uremic Pruritus Program.
Trevi Therapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 08 | 0.95 | 0.84 | 1.02 | 21.77 |
| Dec 09 | 0.90 | 0.81 | 0.94 | 17.29 |
| Dec 10 | 0.80 | 0.75 | 0.84 | 11.54 |
| Dec 11 | 0.86 | 0.81 | 0.94 | 16.17 |
| Dec 12 | 0.98 | 0.95 | 1.09 | 15.67 |
| Dec 13 | 1.07 | 1.02 | 1.18 | 14.92 |
| Dec 14 | 1.01 | 0.98 | 1.04 | 6.66 |
| Dec 15 | 1.02 | 0.92 | 1.08 | 16.95 |
| Dec 16 | 0.99 | 0.91 | 1.10 | 20.04 |
| Dec 17 | 0.87 | 0.83 | 0.97 | 16.97 |
| Dec 18 | 0.79 | 0.74 | 0.87 | 16.78 |
| Dec 19 | 0.78 | 0.74 | 0.81 | 8.69 |
| Dec 20 | 0.74 | 0.69 | 0.78 | 11.61 |
| Dec 21 | 0.75 | 0.70 | 0.79 | 13.97 |
| Dec 22 | 0.83 | 0.78 | 0.92 | 18.54 |
| Dec 23 | 0.77 | 0.68 | 0.83 | 22.22 |
| Dec 24 | 0.80 | 0.71 | 0.84 | 17.96 |
| Dec 25 | 0.87 | 0.77 | 0.96 | 24.89 |
| Dec 26 | 0.80 | 0.76 | 0.85 | 11.87 |
| Dec 27 | 0.77 | 0.70 | 0.86 | 23.08 |
| Dec 28 | 0.82 | 0.73 | 0.90 | 22.63 |
| Dec 29 | 0.82 | 0.74 | 0.90 | 22.03 |
| Dec 30 | 0.94 | 0.84 | 0.98 | 15.84 |
| Dec 31 | 1.00 | 0.96 | 1.08 | 12.43 |
| Jan 01 | 0.98 | 0.88 | 1.03 | 17.15 |
| Jan 02 | 1.02 | 0.92 | 1.08 | 18.34 |
| Jan 03 | 0.98 | 0.90 | 1.08 | 19.65 |
| Jan 04 | 0.85 | 0.77 | 0.94 | 21.87 |
| Jan 05 | 0.73 | 0.68 | 0.82 | 19.53 |
| Jan 06 | 0.78 | 0.71 | 0.81 | 13.78 |
Trevi Therapeutics Daily Price Targets
Trevi Therapeutics Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $0.95.
Negative dynamics for Trevi Therapeutics shares will prevail with possible volatility of 17.875%.
Pessimistic target level: 0.84
Optimistic target level: 1.02
Trevi Therapeutics Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $0.90.
Negative dynamics for Trevi Therapeutics shares will prevail with possible volatility of 14.742%.
Pessimistic target level: 0.81
Optimistic target level: 0.94
Trevi Therapeutics Stock Forecast 12-10-2023.
Forecast target price for 12-10-2023: $0.80.
Negative dynamics for Trevi Therapeutics shares will prevail with possible volatility of 10.350%.
Pessimistic target level: 0.75
Optimistic target level: 0.84
Trevi Therapeutics Stock Forecast 12-11-2023.
Forecast target price for 12-11-2023: $0.86.
Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 13.918%.
Pessimistic target level: 0.81
Optimistic target level: 0.94
Trevi Therapeutics Stock Forecast 12-12-2023.
Forecast target price for 12-12-2023: $0.98.
Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 13.545%.
Pessimistic target level: 0.95
Optimistic target level: 1.09
Trevi Therapeutics Stock Forecast 12-13-2023.
Forecast target price for 12-13-2023: $1.07.
Positive dynamics for Trevi Therapeutics shares will prevail with possible volatility of 12.984%.
Pessimistic target level: 1.02
Optimistic target level: 1.18
TRVI (TRVI) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan. | 1.24 | 1.13 | 1.52 | 26.08 |
| Feb. | 1.23 | 0.98 | 1.34 | 26.70 |
| Mar. | 1.35 | 1.22 | 1.53 | 20.41 |
| Apr. | 0.97 | 0.77 | 1.04 | 26.31 |
| May. | 1.10 | 0.94 | 1.31 | 28.62 |
| Jun. | 1.28 | 1.18 | 1.37 | 14.27 |
| Jul. | 1.33 | 1.08 | 1.58 | 31.37 |
| Aug. | 1.16 | 0.91 | 1.29 | 29.54 |
| Sep. | 1.20 | 1.12 | 1.43 | 21.70 |
| Oct. | 1.29 | 1.12 | 1.57 | 28.55 |
| Nov. | 0.95 | 0.85 | 1.07 | 20.57 |
| Dec. | 0.88 | 0.71 | 0.98 | 27.32 |
Trevi Therapeutics forecast for this year
Trevi Therapeutics Stock Prediction for Jan 2024
An uptrend is forecast for this month with an optimal target price of $1.23637. Pessimistic: $1.13. Optimistic: $1.52
Trevi Therapeutics Stock Prediction for Feb 2024
An downtrend is forecast for this month with an optimal target price of $1.22896. Pessimistic: $0.98. Optimistic: $1.34
Trevi Therapeutics Stock Prediction for Mar 2024
An uptrend is forecast for this month with an optimal target price of $1.35062. Pessimistic: $1.22. Optimistic: $1.53
Trevi Therapeutics Stock Prediction for Apr 2024
An downtrend is forecast for this month with an optimal target price of $0.9738. Pessimistic: $0.77. Optimistic: $1.04
Trevi Therapeutics Stock Prediction for May 2024
An uptrend is forecast for this month with an optimal target price of $1.09942. Pessimistic: $0.94. Optimistic: $1.31
Trevi Therapeutics Stock Prediction for Jun 2024
An uptrend is forecast for this month with an optimal target price of $1.28082. Pessimistic: $1.18. Optimistic: $1.37
Trevi Therapeutics Stock Prediction for Jul 2024
An uptrend is forecast for this month with an optimal target price of $1.33078. Pessimistic: $1.08. Optimistic: $1.58
Trevi Therapeutics Stock Prediction for Aug 2024
An downtrend is forecast for this month with an optimal target price of $1.15911. Pessimistic: $0.91. Optimistic: $1.29
Trevi Therapeutics Stock Prediction for Sep 2024
An uptrend is forecast for this month with an optimal target price of $1.20083. Pessimistic: $1.12. Optimistic: $1.43
Trevi Therapeutics Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $1.2909. Pessimistic: $1.12. Optimistic: $1.57
Trevi Therapeutics Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $0.9501. Pessimistic: $0.85. Optimistic: $1.07
Trevi Therapeutics Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $0.875992. Pessimistic: $0.71. Optimistic: $0.98
Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.05 | 0.83 | 1.26 | 34.47 |
| Feb | 1.05 | 0.83 | 1.19 | 30.13 |
| Mar | 1.25 | 1.03 | 1.55 | 33.71 |
| Apr | 1.31 | 1.05 | 1.48 | 28.77 |
| May | 1.16 | 1.03 | 1.25 | 17.81 |
| Jun | 1.19 | 0.97 | 1.41 | 31.03 |
| Jul | 1.10 | 0.96 | 1.35 | 28.30 |
| Aug | 0.87 | 0.72 | 1.02 | 29.24 |
| Sep | 0.90 | 0.74 | 1.04 | 29.61 |
| Oct | 0.92 | 0.80 | 1.10 | 26.56 |
| Nov | 0.95 | 0.74 | 1.08 | 31.27 |
| Dec | 1.01 | 0.92 | 1.16 | 20.92 |
Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.08 | 0.95 | 1.27 | 25.04 |
| Feb | 0.98 | 0.80 | 1.05 | 23.29 |
| Mar | 1.22 | 1.13 | 1.31 | 13.71 |
| Apr | 0.88 | 0.78 | 0.95 | 18.22 |
| May | 0.71 | 0.64 | 0.78 | 17.20 |
| Jun | 0.51 | 0.41 | 0.60 | 30.66 |
| Jul | 0.49 | 0.39 | 0.51 | 24.34 |
| Aug | 0.62 | 0.55 | 0.72 | 23.57 |
| Sep | 0.73 | 0.62 | 0.79 | 22.48 |
| Oct | 0.77 | 0.59 | 0.85 | 30.51 |
| Nov | 0.76 | 0.69 | 0.90 | 24.10 |
| Dec | 0.69 | 0.58 | 0.77 | 25.25 |
Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 0.79 | 0.70 | 0.87 | 19.55 |
| Feb | 0.74 | 0.62 | 0.84 | 26.42 |
| Mar | 0.87 | 0.73 | 1.00 | 26.75 |
| Apr | 0.74 | 0.63 | 0.86 | 25.76 |
| May | 0.78 | 0.61 | 0.83 | 26.17 |
| Jun | 0.81 | 0.70 | 0.89 | 21.41 |
| Jul | 0.93 | 0.80 | 1.02 | 21.41 |
| Aug | 1.08 | 0.83 | 1.17 | 28.98 |
| Sep | 1.23 | 0.98 | 1.52 | 35.25 |
| Oct | 1.47 | 1.36 | 1.60 | 15.14 |
| Nov | 1.67 | 1.29 | 1.78 | 27.38 |
| Dec | 2.07 | 1.69 | 2.28 | 25.79 |
Trevi Therapeutics (TRVI) Monthly Stock Prediction for 2028
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.82 | 1.49 | 2.04 | 26.79 |
| Feb | 2.31 | 2.11 | 2.45 | 13.87 |
| Mar | 2.19 | 1.92 | 2.72 | 29.52 |
| Apr | 1.70 | 1.41 | 1.81 | 22.23 |
| May | 1.57 | 1.34 | 1.80 | 25.57 |
| Jun | 1.35 | 1.26 | 1.49 | 15.24 |
| Jul | 1.49 | 1.20 | 1.82 | 34.29 |
| Aug | 1.44 | 1.21 | 1.54 | 21.05 |
| Sep | 1.49 | 1.41 | 1.62 | 13.28 |
| Oct | 1.77 | 1.38 | 2.14 | 35.29 |
| Nov | 2.09 | 1.69 | 2.34 | 28.05 |
| Dec | 2.71 | 2.24 | 3.23 | 30.88 |
Trevi Therapeutics information and performance
195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, US
Market capitalization of the Trevi Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TRVI shares in the company outstanding by the market price of one share.
EBITDA of Trevi Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
